Brief: Innate Pharma Presents Positive Results From Tellomak Phase 2 Study With Lacutamab In Patients With Sézary Syndrome At Ash 2023
10/12/2023 08:21
Dec 10 (Reuters) - Innate Pharma SA IPH.PA :
* INNATE PHARMA PRESENTS POSITIVE RESULTS FROM TELLOMAK
PHASE 2
STUDY WITH LACUTAMAB IN PATIENTS WITH SÉZARY SYNDROME AT ASH
2023
Source text for Eikon: ID:nBw13VvTSa
Further company coverage: IPH.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innate Pharma SA
See all newsBrief: Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502
France's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member